Jessica Donington, MD, MSCR: There’s one more factor that in 2021 plays a huge role in how we determine upfront treatment and treatment plans altogether and that’s something called molecular testing.
Two medical oncologists break down the role molecular testing has when treating NSCLC, from guidelines to common methods to barriers. Joshua Sabari, MD: I recommend testing up front. All patients with ...
IVDR: where are we now in molecular testing? How IVDR implementation is progressing in molecular biology laboratories in different European countries IVDR, the new EU legislation for in-vitro ...
Molecular testing, including chromosomal microarray analysis, distinguishes between aggressive and indolent kidney cancer subtypes, aiding in accurate diagnosis. Accurate diagnosis is critical for ...
ROCKVILLE, Md. – August 19, 2024 – The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, and world-renowned pathologist Michael Laposata, MD, PhD ...
We reviewed the latest evidence and plan to update the recommendations on testing for Lynch syndrome using next generation sequencing. For more information, see the review decision. Diagnostics ...
Antimicrobial resistance (AMR) remains a major global healthcare challenge, undermining the effectiveness of treatments for common infections and threatening modern medical advances. Improved ...
3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test. 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from ...
Alexander Spira, MD, PhD, FACP provides an overview of molecular testing in NSCLC. Alexander Spira, MD, PhD, FACP: Guidelines and recommendations around molecular testing in advanced non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results